BioTech IQ

67 Episodes

1. #47 Can Hepion Pharmaceuticals Develop the First Treatment Approved For NASH? With Robert Foster, Pharm D, PhD

   Published: 4/29/2022
2. #46 How Is Translational Genomics Reducing Background Noise In Multi-Disease Detection? With Aiguo "Adam" Zhang

   Published: 4/22/2022
3. #45 Does company culture really affect drug development?

   Published: 4/15/2022
4. #44 Addressing One Of The World’s Biggest Drivers Of Disease: Inflammation With Jim Woody, M.D., Ph.D. - CEO 180 Life Sciences

   Published: 4/1/2022
5. #43 How to leverage past experience in developing treatments for rare disease. James Mackay, PhD - CEO, Aristea Therapeutics

   Published: 3/25/2022
6. #42 Regenerative Medicine? How two companies are attacking nerve damage.

   Published: 3/12/2022
7. #41 Is axonal transport the key to solving neurodegenerative diseases? Maria Maccechini, PhD - CEO, Annovis Bio

   Published: 3/4/2022
8. #40 Treatments that can reach beyond on the function of drugs? James Joyce, CEO - Sigyn Therapeutics

   Published: 2/25/2022
9. #39 How can digital health change the success of patient care? Waqaas Al-Siddiq, DBA, CEO - Biotricity

   Published: 2/18/2022
10. Bonus Episode! Digital Health Panel with Biotricity and DarioHealth

    Published: 2/17/2022
11. #37 How many lives would be changed with effective prevention of thromboembolic events? John Glasspool, CEO of Anthos Therapeutics

    Published: 2/11/2022
12. #36 Can Shoreline Biosciences change the future of cell therapy through pluripotent stem cells?

    Published: 2/4/2022
13. #35 Can Biomea Change the World with Irreversible Drugs and Covalent Bonds? Thomas Butler, CEO - Biomea Fusion

    Published: 1/4/2022
14. #33 Reducing friction at Clinical Trial Start-Up - Sam Searcy, CEO of CliniStart

    Published: 12/18/2021
15. #32 People, the most valuable asset a business has. Brenda Sousa - Chief HR Officer

    Published: 12/13/2021
16. #31 Managing CRO relationships and unique business models - Stewart Hallet - COO SFJ Pharmaceuticals

    Published: 11/24/2021
17. #30 Brazen Bio Part II - Live and In Person!

    Published: 11/4/2021
18. #29 Why do we resist? Applying clinical psychology to clinical trials. Kathleen Starr, PhD - EVP Behavioral Insights, Syneos Health

    Published: 10/29/2021
19. #28 Vaccine Durability, Diversified Pipeline, Winning Strategy - Seth Lederman, MD - CEO Tonix Pharmaceuticals

    Published: 10/1/2021
20. #27 How do you effectively manage the CMC process? With Doug Looker, PhD

    Published: 9/21/2021